Could baseline ctDNA and methylation status predict treatment benefit in advanced breast cancer?

We recently spoke with Seth Wander of Harvard Medical School and Massachusetts General Hospital (MA, USA) to discuss the key insights from the session he chaired on CDK4/6 inhibitors at ESMO Breast Cancer 2025 (14–17 May, Munich, Germany). In the interview, Seth Wander shares his conference highlights, outlines the next steps for the post-MONARCH trial and discusses his thoughts on the potential role of methylation status and baseline ctDNA in predicting treatment response for advanced breast cancer patients. Could you give us key takeaways from the session you chaired titled continuing CDK4/6 inhibitors after progression? Is it good enough? It...